We examined how a special probiotic mix, known as IRT5, affects autoimmune diabetes in non-obese diabetic (NOD) mice. Administered frequently over 36 weeks, this combination not only reduced diabetes incidence but also lowered insulitis scores and increased insulin-producing β-cell mass.
Additionally, IRT5 improved gut health and changed the makeup of immune cells in the pancreas and intestines. While some immune responses stayed the same, the shift towards more gut-focused regulatory T cells suggests it could be a promising treatment for type 1 diabetes.
Read More
Synbiotics improve rheumatoid arthritis symptomsSynbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial.
High relevance; significant findings
We investigated how synbiotic supplementation affects patients with rheumatoid arthritis (RA). In an 8-week, randomized, double-blind trial involving 54 participants, we compared the outcomes of those taking synbiotic capsules with a placebo group.
After the trial, those who received synbiotics showed a significant drop in inflammation markers and pain levels. Additionally, improvements were observed in insulin resistance and overall metabolic responses.
These findings suggest that synbiotics might benefit individuals managing RA by reducing inflammation and enhancing metabolic health.
Read More
We explored how specific Lactobacillus acidophilus strains can impact autoimmune disorders by reducing leptin production in mice. In our study, we compared the effects of CBA4P and other lactobacilli on adipocytes from mice sensitive to Th1 immune diseases.
Results showed that CBA4P significantly lowered leptin levels and inhibited the activation of immune lymphocytes in the SJL mouse strain. This suggests that CBA4P might help manage Th1-related inflammatory conditions, representing a potentially valuable probiotic option for autoimmune control.
Read More
Lactic acid bacteria combat autoimmune symptomsThe Role of Lactic Acid Bacteria in Improving Behavioral Deficits, Serum Levels of Vitamin D3, B12 and Reducing Oxidative Stress and Demyelination in a Cuprizone-induced Demyelination Model of Rat.
Study shows potential therapeutic role
We investigated the potential of Lactobacillus and Bifidobacterium in alleviating symptoms of multiple sclerosis using a rat model. The study involved 48 male rats, which were divided into groups to evaluate the effects of these bacteria on demyelination caused by cuprizone.
The results showed that treatment with lactic acid bacteria notably improved behavioral impairments, decreased demyelination, reduced oxidative stress, and elevated serum levels of vitamins D and B.
Overall, these findings indicate that Lactobacillus and Bifidobacterium may be beneficial in managing autoimmune conditions like multiple sclerosis.
Read More
Synbiotics reduce lupus activityImpact of synbiotics on disease activity in systemic lupus erythematosus: Results from a randomized clinical trial.
5599: Relevant for autoimmune treatment
This randomized, double-blind trial sought to see how synbiotics, including Lactobacillus acidophilus, could help patients with systemic lupus erythematosus (SLE). Fifty patients were divided into two groups: one received synbiotics alongside their standard therapy, while the other got standard therapy alone over two months.
We observed that those who took the synbiotics showed a meaningful drop in inflammatory markers like interleukin-17A and overall disease activity. Meanwhile, the placebo group didn’t see these improvements. While these findings are promising, we recognize that more research is necessary to fully understand how synbiotics work in SLE management.
Read More